KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Assets (2016 - 2025)

Historic Assets for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $3.0 billion.

  • Ionis Pharmaceuticals' Assets fell 155.81% to $3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year decrease of 155.81%. This contributed to the annual value of $3.0 billion for FY2024, which is 45.49% up from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Assets stood at $3.0 billion, which was down 155.81% from $3.0 billion recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Assets ranged from a high of $3.1 billion in Q3 2024 and a low of $2.2 billion during Q1 2021
  • Its 5-year average for Assets is $2.7 billion, with a median of $2.8 billion in 2024.
  • In the last 5 years, Ionis Pharmaceuticals' Assets tumbled by 2725.29% in 2021 and then surged by 2113.98% in 2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Assets (Quarter) stood at $2.6 billion in 2021, then fell by 2.98% to $2.5 billion in 2022, then increased by 18.0% to $3.0 billion in 2023, then increased by 0.45% to $3.0 billion in 2024, then increased by 0.98% to $3.0 billion in 2025.
  • Its Assets stands at $3.0 billion for Q3 2025, versus $3.0 billion for Q2 2025 and $2.8 billion for Q1 2025.